Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Progressive Fibrosing ILD (INBUILD)
NCT02999178Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2017
- Primary completion
- Apr 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 15
01
Overview
A Phase 3 trial of nintedanib in progressive fibrosing interstitial lung disease (PF-ILD), sponsored by Boehringer Ingelheim. Started Jan 2017; status: completed.
02
Drugs
nintedanib
03
Conditions
progressive fibrosing interstitial lung disease (PF-ILD)
Beyond the preview
Go deeper on NCT02999178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02999178.